MCID: ACT011
MIFTS: 51

Acute Contagious Conjunctivitis

Categories: Eye diseases, Infectious diseases

Aliases & Classifications for Acute Contagious Conjunctivitis

MalaCards integrated aliases for Acute Contagious Conjunctivitis:

Name: Acute Contagious Conjunctivitis 12 15 74
Pink Eye 12 3
Pinkeye 12 44
Keratoconjunctivitis Due to Mycoplasma Conjunctivae 74
Contagious Opthalmia 12
Conjunctivitis 74

Classifications:



External Ids:

Disease Ontology 12 DOID:11213
NCIt 51 C35704
SNOMED-CT 69 17482009
ICD10 34 B30.0

Summaries for Acute Contagious Conjunctivitis

MedlinePlus : 44 Conjunctivitis is the medical name for pink eye. It involves inflammation of the outer layer of the eye and inside of the eyelid. It can cause swelling, itching, burning, discharge, and redness. Causes include Bacterial or viral infection Allergies Substances that cause irritation Contact lens products, eye drops, or eye ointments Pinkeye usually does not affect vision. Infectious pink eye can easily spread from one person to another. The infection will clear in most cases without medical care, but bacterial pinkeye needs treatment with antibiotic eye drops or ointment. NIH: National Eye Institute

MalaCards based summary : Acute Contagious Conjunctivitis, also known as pink eye, is related to albinism, oculocutaneous, type ii and albinism, oculocutaneous, type iii, and has symptoms including fever, pruritus and bloodshot eye. An important gene associated with Acute Contagious Conjunctivitis is OCA2 (OCA2 Melanosomal Transmembrane Protein), and among its related pathways/superpathways are ALK1 signaling events and Follicle Stimulating Hormone (FSH) signaling pathway. The drugs Bepotastine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are Decreased human cytomegalovirus (HCMV) strain AD169 replication and Decreased substrate adherent cell growth

Disease Ontology : 12 A bacterial acute conjunctivitis that is characterized by highly contagious conjunctival hypermia and mucopurulent discharge and has_material basis in Hemophilius Aegypticus.

CDC : 3 People often call conjunctivitis “pink eye” because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Related Diseases for Acute Contagious Conjunctivitis

Graphical network of the top 20 diseases related to Acute Contagious Conjunctivitis:



Diseases related to Acute Contagious Conjunctivitis

Symptoms & Phenotypes for Acute Contagious Conjunctivitis

UMLS symptoms related to Acute Contagious Conjunctivitis:


fever, pruritus, bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

GenomeRNAi Phenotypes related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.46 ACVR1 ACVRL1 CKM PRKCG
2 Decreased substrate adherent cell growth GR00193-A-1 9.43 ACVR1 ACVRL1 PRKCG
3 Decreased substrate adherent cell growth GR00193-A-3 9.43 ACVR1
4 Decreased substrate adherent cell growth GR00193-A-4 9.43 ACVR1 ACVRL1
5 Increased cell viability after pRB stimulation GR00230-A-1 8.92 ACVR1 ACVRL1 CKM PRKCG

MGI Mouse Phenotypes related to Acute Contagious Conjunctivitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 ACVR1 ACVRL1 APPL1 CYP19A1 KCNH1 MC1R
2 cellular MP:0005384 10.1 ACVR1 APPL1 BLVRA CKM CYP19A1 FH
3 growth/size/body region MP:0005378 10.07 ACVR1 ACVRL1 APPL1 CKM CYP19A1 GPI
4 homeostasis/metabolism MP:0005376 10.03 ACVR1 ACVRL1 APPL1 BLVRA CKM CYP19A1
5 hearing/vestibular/ear MP:0005377 9.8 ACVR1 CYP19A1 MC1R OCA2 TLR4 TYR
6 liver/biliary system MP:0005370 9.63 ACVRL1 BLVRA CYP19A1 GPI OCA2 TLR4
7 pigmentation MP:0001186 9.35 CYP19A1 MC1R OCA2 TLR4 TYR
8 renal/urinary system MP:0005367 9.1 ACVRL1 CYP19A1 FH OCA2 TLR4 TYR

Drugs & Therapeutics for Acute Contagious Conjunctivitis

Drugs for Acute Contagious Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 399)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bepotastine Approved Phase 4,Phase 2,Phase 3 190786-44-8, 125602-71-3 2350
2
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
3
Pheniramine Approved Phase 4 86-21-5 4761
4
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
6
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
7
Naphazoline Approved, Investigational Phase 4,Phase 3 835-31-4 4436
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
9
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
13
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
14
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
15
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 6473866 445643 439492
16
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
17
Povidone Approved Phase 4,Phase 3,Not Applicable 9003-39-8
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
19
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
20
Polymyxin B Approved, Vet_approved Phase 4,Phase 3 1404-26-8
21
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 82410-32-0 3454
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
24
Ketotifen Approved Phase 4,Phase 3,Phase 1,Phase 2 34580-14-8, 34580-13-7 3827
25
Dipivefrin Approved Phase 4,Phase 3,Phase 2,Phase 1 52365-63-6 3105
26
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 36294 5496
27
Iodine Approved, Investigational Phase 4,Phase 3,Not Applicable 7553-56-2 807
28
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-81-5 753
29
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
30
Fluorometholone Approved, Investigational Phase 4,Phase 3,Not Applicable 426-13-1 9878
31
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
32
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
33
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
34
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
35
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
36
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
37
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
38
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
39
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
40
Epinephrine Approved, Vet_approved Phase 4,Phase 3 51-43-4 5816
41
Racepinephrine Approved Phase 4,Phase 3 329-65-7 838
42
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
43
Montelukast Approved Phase 4 158966-92-8 5281040
44
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 447043 55185
45
Permethrin Approved, Investigational Phase 4,Phase 2 52645-53-1 40326
46
Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
47
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
48
Menthol Approved Phase 4 2216-51-5 16666
49
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
50
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538

Interventional clinical trials:

(show top 50) (show all 981)
# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Unknown status NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
4 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
5 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
6 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
7 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
9 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
10 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
11 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
12 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
13 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
14 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
15 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
16 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
17 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
18 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
19 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
20 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
21 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
22 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
23 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
24 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
25 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
26 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
27 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
28 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
29 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
30 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
31 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
32 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
33 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
34 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
35 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
36 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
37 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
38 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
39 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
40 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
41 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
42 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
43 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
44 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Completed NCT02256553 Phase 4 Rescue Medication
45 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
46 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
47 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
48 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
49 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
50 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone

Search NIH Clinical Center for Acute Contagious Conjunctivitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Acute Contagious Conjunctivitis

Anatomical Context for Acute Contagious Conjunctivitis

MalaCards organs/tissues related to Acute Contagious Conjunctivitis:

42
Eye, Testes, Skin, Thyroid, Salivary Gland, Bone, B Cells

Publications for Acute Contagious Conjunctivitis

Articles related to Acute Contagious Conjunctivitis:

(show all 23)
# Title Authors Year
1
Tear Film Amphiphilic and Anti-Inflammatory Lipids in Bovine Pink Eye. ( 30469369 )
2018
2
Anisocoria Secondary to Anticholinergic Mydriasis from Homeopathic Pink Eye Relief Drops. ( 29042447 )
2017
3
Effect of "Pink Eye" Label on Parents' Intent to Use Antibiotics and Perceived Contagiousness. ( 26294761 )
2016
4
Pink eye and discharge for 18 months. ( 23914790 )
2013
5
Patient information. Pink eye: what you should know. ( 20112458 )
2010
6
The rat pink-eyed dilution (p) mutation: an identical intragenic deletion in pink-eye dilute-coat strains and several Wistar-derived albino strains. ( 16245028 )
2005
7
Physical and linkage mapping of the porcine pink-eye dilution gene ( OCA2 ). ( 12354157 )
2002
8
A possible cause for the 'pink-eye-like' condition in red deer. ( 16031072 )
1984
9
Inclusion keratoconjunctivitis ('pink eye') in sheep. A proposal for a new name for chlamydial keratoconjunctivitis in sheep and comment on recent clinical trials. ( 6093332 )
1984
10
Pink-eye--a new sex-linked mutant of Culex quinquefasciatus. ( 6585350 )
1983
11
Keratoconjunctivitis infectiosa ovis (KIO), 'pink eye' or 'zere oogjes' (a survey). ( 6356577 )
1983
12
'Pink eye' or 'zere oogjes' or keratoconjunctivitis infectiosa ovis (KIO). Clinical efficacy of a number of antimicrobial therapies. ( 6195802 )
1983
13
Mycoplasma aetiology of keratoconjunctivitis ("pink-eye") in domestic ruminants. ( 4207039 )
1973
14
Mycoplasma and associated bacteria isolated from ovine pink-eye. ( 4251781 )
1971
15
Ultrastructural differences between forming eumelanin and pheomelanin as revealed by the pink-eye mutation in the fowl. ( 5719204 )
1968
16
Cytology of "pink-eye" of sheep, including a reference to trachoma of man, by employing acridine orange and iodine stains, and isolation of Mycoplasma agents from infected sheep eyes. ( 4174125 )
1968
17
Infectious keratoconjunctivitis (pink eye) in cattle in Orissa. ( 6008082 )
1966
18
ISOLATION OF AN AGENT PRODUCING OVINE INFECTIOUS KERATOCONJUNCTIVITIS (PINK EYE). ( 14299415 )
1965
19
The use of cortisone in the treatment of infectious keratoconjunctivitis (pink-eye) in cattle. ( 13416098 )
1957
20
Test of correlation between the pink-eye gene and susceptibility to induced fibrosarcoma in mice. ( 14792553 )
1951
21
Graft compatibility of the "pink eye" gene in mice. ( 14822967 )
1951
22
Management of pink eye. ( 14824789 )
1951
23
Tumor development in backcross mice segregated with respect to the hairless and the pink-eye genes. ( 14889249 )
1951

Variations for Acute Contagious Conjunctivitis

Expression for Acute Contagious Conjunctivitis

Search GEO for disease gene expression data for Acute Contagious Conjunctivitis.

Pathways for Acute Contagious Conjunctivitis

Pathways related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.59 ACVR1 ACVRL1
2 10.39 APPL1 CYP19A1
3 9.32 OCA2 TYR

GO Terms for Acute Contagious Conjunctivitis

Cellular components related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome membrane GO:0033162 8.96 OCA2 TYR
2 activin receptor complex GO:0048179 8.62 ACVR1 ACVRL1

Biological processes related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007178 9.37 ACVR1 ACVRL1
2 activin receptor signaling pathway GO:0032924 9.32 ACVR1 ACVRL1
3 endocardial cushion morphogenesis GO:0003203 9.26 ACVR1 ACVRL1
4 eye pigment biosynthetic process GO:0006726 9.16 OCA2 TYR
5 pigmentation GO:0043473 9.13 MC1R OCA2 TYR
6 melanin biosynthetic process GO:0042438 8.8 MC1R OCA2 TYR

Molecular functions related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transforming growth factor beta binding GO:0050431 9.4 ACVR1 ACVRL1
2 transforming growth factor beta-activated receptor activity GO:0005024 9.37 ACVR1 ACVRL1
3 activin binding GO:0048185 9.32 ACVR1 ACVRL1
4 transmembrane receptor protein serine/threonine kinase activity GO:0004675 9.26 ACVR1 ACVRL1
5 BMP receptor activity GO:0098821 9.16 ACVR1 ACVRL1
6 transforming growth factor beta receptor activity, type I GO:0005025 8.96 ACVR1 ACVRL1
7 activin receptor activity, type I GO:0016361 8.62 ACVR1 ACVRL1

Sources for Acute Contagious Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....